Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2016 1
2020 1
2021 1
2022 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, Criner GJ, Kaplan-Lewis E, Baden R, Pandit L, Cameron ML, Garcia-Diaz J, Chávez V, Mekebeb-Reuter M, Lima de Menezes F, Shah R, González-Lara MF, Assman B, Freedman J, Mohan SV. Salama C, et al. Among authors: neidhart jd. N Engl J Med. 2021 Jan 7;384(1):20-30. doi: 10.1056/NEJMoa2030340. Epub 2020 Dec 17. N Engl J Med. 2021. PMID: 33332779 Free PMC article. Clinical Trial.
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Afari J, Spektor TM, Turner C, Cohen A, Bessudo A, Jhangiani H, Gabrail N, Kubba S, Neidhart JD, Eshaghian S, Swift RA, Eades BM, Kim C, Kim S, Vescio R, Berenson JR. Afari J, et al. Among authors: neidhart jd. Exp Hematol. 2022 Oct;114:54-60. doi: 10.1016/j.exphem.2022.07.303. Epub 2022 Aug 4. Exp Hematol. 2022. PMID: 35934183 No abstract available.
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies.
Weiss GJ, Chao J, Neidhart JD, Ramanathan RK, Bassett D, Neidhart JA, Choi CHJ, Chow W, Chung V, Forman SJ, Garmey E, Hwang J, Kalinoski DL, Koczywas M, Longmate J, Melton RJ, Morgan R, Oliver J, Peterkin JJ, Ryan JL, Schluep T, Synold TW, Twardowski P, Davis ME, Yen Y. Weiss GJ, et al. Among authors: neidhart jd. Invest New Drugs. 2013 Aug;31(4):986-1000. doi: 10.1007/s10637-012-9921-8. Epub 2013 Feb 9. Invest New Drugs. 2013. PMID: 23397498 Free PMC article. Clinical Trial.
A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.
Garon EB, Neidhart JD, Gabrail NY, de Oliveira MR, Balkissoon J, Kabbinavar F. Garon EB, et al. Among authors: neidhart jd. Onco Targets Ther. 2016 Nov 30;9:7275-7283. doi: 10.2147/OTT.S109186. eCollection 2016. Onco Targets Ther. 2016. PMID: 27942221 Free PMC article.